Ultimovacs’ UV1 cancer vaccine shows strong overall survival in malignant melanoma phase I trial
- 30 patients treated with UV1/pembrolizumab
- 24-month survival rate of 73%
- Promising survival data follows encouraging clinical response rates and good safety
Oslo, 20 June 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announced today positive 2-year overall survival data in its ongoing phase I clinical study of the cancer vaccine UV1 in combination with pembrolizumab for the treatment of malignant melanoma. Across all 30 patients in the study, the 24-month survival rate was 73%. Patients will continue to be followed for long-term survival.
“This result is the latest in a stream of highly encouraging data that indicate the effectiveness of UV1 in enhancing treatment of malignant melanoma. It underlines the potential of UV1 in promoting a concerted immune response in many solid tumor types including those in Ultimovacs’ broader phase II programs.” said Carlos de Sousa, Chief Executive Officer of Ultimovacs. “We have seen consistently more positive outcomes from UV1 in combination with pembrolizumab than with the checkpoint inhibitor alone - higher complete response rates, higher overall response rates, higher median progression-free survival and now better 24-month overall survival rates.”
In the same malignant melanoma study, as reported in March 2022, the complete response rate is 33% (i.e. with complete disappearance of tumors) and the objective response rate is 57% (i.e. with a partial or complete disappearance of tumors). Earlier trials with checkpoint inhibitors have shown that patients with clinical responses have improved survival rates.
The data represent the latest result from Ultimovacs’ phase I study of its universal cancer vaccine UV1 used in combination with the PD-1 checkpoint inhibitor pembrolizumab. Thirty patients were treated in the study in two cohorts that differed only in the concentration of GM-CSF used as a vaccine adjuvant. Two years have passed since the beginning of treatment of the last patient in the second cohort. Ultimovacs expects to provide 3-year overall survival data from the first cohort of 20 patients in Q4 2022.
UV1 is a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. It is being developed as an “off-the-shelf” therapeutic cancer vaccine for use in combination with other immunotherapies that require an ongoing T cell response for their mode of action. In four Phase I trials involving 82 patients, UV1 has maintained a positive safety and tolerability profile and has demonstrated encouraging signals of efficacy. In 2021, the U.S. FDA granted Fast Track designation to UV1 as add-on therapy to ipilimumab or to pembrolizumab for the treatment of unresectable or metastatic melanoma, as well as Orphan Drug designation to UV1 for the treatment of stage IIB – IV melanoma.
Ultimovacs is developing immune-stimulatory vaccines to treat a broad range of cancers. Ultimovacs’ lead universal cancer vaccine candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in all stages of tumor growth. By directing the immune system to hTERT antigens, UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade and increase anti-tumor responses. With a broad Phase II program in five cancer indication enrolling more than 650 patients, Ultimovacs aims to clinically demonstrate UV1’s impact in multiple cancer types in combination with other immunotherapies, for patients with unmet needs. Ultimovacs’ second technology approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform, combines tumor-specific peptides and adjuvant in the same molecule and entered Phase I studies in 2021.
For further information, please see www.ultimovacs.com or contact:
Carlos de Sousa, CEO
Phone: +47 908 92507
Anne Worsøe, Head of IR & Communication
Phone: +47 906 86815
Mary-Ann Chang, LifeSci Advisors
Phone: +44 7483 284 853
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.
This stock exchange announcement was published by Joachim Midttun, Finance Manager at Ultimovacs ASA, on 20 June, 2022at 08:00 CET.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Cool Company Ltd. - Formation Completed1.7.2022 18:37:43 CEST | Press release
Cool Company Ltd. ("CoolCo" or the "Company") is pleased to announce today that it has acquired from Golar Management (Bermuda) Limited the management organization responsible for the technical and commercial management of its LNG carriers and the provision of such services to third parties, as contemplated in the January 2022 Cool Company Ltd. formation update. CoolCo paid the previously agreed purchase price of $5 million in cash for the shares plus $1.5 million in working capital. As part of the transaction, approximately 600 maritime and office-based personnel become employees of CoolCo. Today, Richard Tyrrell also assumed his position as CEO of CoolCo, replacing interim CEO Karl Fredrik Staubo. Richard Tyrrell commented: “CoolCo is delighted to formally welcome the members of the Golar LNG team that provide first class technical and commercial management services to our owned fleet of eight LNG carriers, in addition to providing such services to 20 third party vessels. The acquisi
U.S. Government Orders Additional Monkeypox Vaccines from Bavarian Nordic1.7.2022 16:00:10 CEST | Press release
Bavarian Nordic to supply an additional 2.5 million doses of JYNNEOS® vaccineDoses will be manufactured using existing bulk vaccine from previous orders from BARDADeliveries starting in the fourth quarter of 2022 with the majority to be delivered in 2023 COPENHAGEN, Denmark, July 1, 2022 – Bavarian Nordic A/S (OMX: BAVA) announced today that the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has ordered an additional 2.5 million doses of liquid-frozen JYNNEOS®, a non-replicating smallpox vaccine and the only FDA-approved vaccine against monkeypox. Deliveries under this contract will start in the fourth quarter of 2022 and continue through early 2023. This order comes a few weeks after an order from BARDA for the delivery of 500,000 doses of the vaccine in 2022 in response to the current monkeypox outbreak. With a previous order from BARD
Den amerikanske regering bestiller yderligere vacciner mod abekopper fra Bavarian Nordic1.7.2022 16:00:10 CEST | pressemeddelelse
Bavarian Nordic skal levere yderligere 2,5 mio. doser JYNNEOS® vaccineRåvaccine, produceret under tidligere kontrakter med BARDA, vil blive anvendt til færdigproduktion af doserneLeverancerne vil starte i fjerde kvartal 2022 og fortsætte ind i 2023, hvor hovedparten af doserne vil blive leveret KØBENHAVN, Danmark, 1. juli 2022 – Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at Biomedical Advanced Research and Development Authority (BARDA), en del af Office of the Assistant Secretary for Preparedness and Response ved U.S. Department of Health and Human Services, har bestilt yderligere 2,5 mio. doser af den flydende-frosne udgave af JYNNEOS®, en ikke-replikerende koppevaccine, og den eneste FDA-godkendte vaccine mod abekopper. Leverancerne vil starte i fjerde kvartal 2022 og fortsætte ind i begyndelsen af 2023. Denne ordre er afgivet få uger efter en anden ordre fra BARDA på levering af 500.000 doser af vaccinen i 2022 til brug i forbindelse med det aktuelle udbrud af abekopper. Med en
Incap Corporation: INCAP GROUP’S HALF-YEAR FINANCIAL REPORT FOR JANUARY–JUNE 2022 AND WEBCAST 28 JULY 20221.7.2022 14:30:00 CEST | Press release
Incap Corporation Press release 1 July 2022 at 3:30 p.m. EEST The corrected release includes the time of the webcast. Incap Group’s half-year financial report for January–June 2022 will be published on Thursday, 28 July 2022 at approximately 09:00 a.m. Finnish time. At that time, reporting materials in Finnish and English will be available on the company's website at https://incapcorp.com/reports-and-presentations/. Webcast The company will hold a webcast on Thursday, 28 July 2022 at 2:00 p.m. EEST. The result will be presented by Otto Pukk, CEO, and Antti Pynnönen, CFO, Incap Corporation. In addition to the result, Incap's UK operations will be presented at the event, and Jamie Maughan, Director of Operations UK will participate in the event. The live webcast can be followed at https://incap.videosync.fi/2022-07-28-half-year-report. During the webcast, the public can ask questions in the chat room at the address mentioned above. The recording of the broadcast will be available on the
Incap Corporation: INCAP GROUP’S HALF-YEAR FINANCIAL REPORT FOR JANUARY–JUNE 2022 AND WEBCAST 28 JULY 20221.7.2022 14:00:00 CEST | Press release
Incap Corporation Press release 1 July 2022 at 3:00 p.m. EEST Incap Group’s half-year financial report for January–June 2022 will be published on Thursday, 28 July 2022 at approximately 09:00 a.m. Finnish time. At that time, reporting materials in Finnish and English will be available on the company's website at https://incapcorp.com/reports-and-presentations/. Webcast The company will hold a webcast on Thursday, 28 July 2022 at xx:00 p.m. EEST. The result will be presented by Otto Pukk, CEO, and Antti Pynnönen, CFO, Incap Corporation. In addition to the result, Incap's UK operations will be presented at the event, and Jamie Maughan, Director of Operations UK will participate in the event. The live webcast can be followed at https://incap.videosync.fi/2022-07-28-half-year-report. During the webcast, the public can ask questions in the chat room at the address mentioned above. The recording of the broadcast will be available on the company's website at https://incapcorp.com/reports-and-